Sanofi (NASDAQ:SNY) Shares Bought by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. raised its stake in Sanofi (NASDAQ:SNYFree Report) by 47.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 10,969 shares of the company’s stock after purchasing an additional 3,514 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Sanofi were worth $545,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Clearbridge Investments LLC raised its position in Sanofi by 8.4% in the 3rd quarter. Clearbridge Investments LLC now owns 184,630 shares of the company’s stock valued at $9,904,000 after purchasing an additional 14,362 shares in the last quarter. Dynamic Advisor Solutions LLC acquired a new stake in shares of Sanofi during the 4th quarter worth about $2,104,000. Soros Fund Management LLC acquired a new stake in shares of Sanofi during the 3rd quarter worth about $11,533,000. International Assets Investment Management LLC acquired a new stake in shares of Sanofi during the 4th quarter worth about $4,704,000. Finally, Clear Street Markets LLC raised its position in shares of Sanofi by 352.8% during the 3rd quarter. Clear Street Markets LLC now owns 130,183 shares of the company’s stock worth $6,983,000 after acquiring an additional 101,430 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SNY shares. Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price on the stock. TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Get Our Latest Research Report on SNY

Sanofi Trading Up 1.9 %

Shares of SNY stock opened at $50.21 on Tuesday. The business’s 50 day moving average is $48.11 and its two-hundred day moving average is $48.03. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.72. The company has a market capitalization of $127.01 billion, a P/E ratio of 25.23, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a $1.478 dividend. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is 74.37%.

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Read More

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.